Avoid common mistakes on your manuscript.
IDH-mutant astrocytomas (IDHA) are initially slow-growing tumors that almost inevitably progress [4]. Homozygous deletion (HOMDEL) of CDKN2A and/or CDKN2B (CDKN2A/B), now a WHO grade 4 defining criterion for IDHA, is associated with rapid progression and poor overall survival (OS) [1, 9]. We examined the prognostic significance of additional CDKN2A/B inactivating events, including nonsynonymous mutations and allele-specific copy number alterations (ASCNA) by analyzing 347 prospectively tumor-matched normal sequenced IDHA (347 patients, supplemental table 1) using FACETS (Fraction and Allele-Specific Copy Number Estimates from Tumor Sequencing), a SNP-based algorithm to assess ASCNA across genomic targets [8], with validation using The Cancer Genome Atlas (TCGA, 188 tumors/patients, supplemental methods).
CDKN2A/B alterations were found in up to 15% of IDHA (Fig. 1a, b): 12% exhibited CDKN2A/B loss (n = 42/347) and were associated with higher histologic grade (supplemental table 2). CDKN2A/B loss, PDGFRA gain, and CDK4 gain associated with shorter OS by multivariable Cox proportional hazards modelling (supplemental Fig. 1e). Nonsynonymous mutations in CDKN2A were uncommon (n = 9, 2.6%), but were mostly classified as oncogenic or likely oncogenic by OncoKB™ (n = 6, Fig. 1b, supplemental table 3) [2]. CDKN2A-mutant tumors were higher grade and had shortened OS (median OS: 1.6 years, 95% CI: 0.8 years–not reached [NR]) versus non-mutant tumors (median OS: 12.6 years, 95% CI: 11.4 years–NR, P < 0.001, Fig. 1c), approximating the OS of tumors with CDKN2A/B copy loss (median survival: 3.0 years, CI: 1.4 years–NR) even after excluding hypermutant tumors [10].
FACETS detected hemizygous deletion (HEMIDEL) in 23% of IDHA (n = 81/347), HOMDEL in 6% (n = 21), and copy-neutral loss of heterozygosity (CNLOH) in 3% (n = 11), mostly in high histologic grade tumors (supplemental table 4). The remaining 67% (n = 234) were neutral (supplemental Fig. 2a). Of 305 copy neutral tumors, FACETS detected ASCNA in 75 (25%) demonstrating shorter OS (median 7.0 years, 95% CI: 5.9 years–NR) vs. FACETS neutral (15.4 years, 95% CI: 11.8 years–NR, P = 0.0014, Fig. 1d). HEMIDEL IDHA had shorter OS than neutral (median survival: 6.9 years (95% CI: 4.5 years–NR) vs. 15.4 years (95% CI: 11.8 years–NR, P < 0.001), but longer OS than HOMDEL/mutant cases (median survival: 2.6 years, 95% CI: 1.3 years–NR, P = 0.018, Fig. 1e). CNLOH of CDKN2A/B portended poor prognosis (median survival: 2.3 years, 95% CI: 1.6 years–NR, P < 0.001, supplemental Fig. 2b). We verified intermediate OS of CDKN2A/B HEMIDEL between CDKN2A/B HOMDEL/mutant and neutral tumors (Fig. 1f) in the TCGA cohort (supplemental methods). Gains of CDK4 and/or CCND2 worsened OS in CDKN2A/B HEMIDEL tumors (median survival: 3.2 years (95% CI: 1.4 years–NR) versus 11.5 years (95% CI: 4.5 years-NR, P = 0.011, supplemental Fig. 2c, d).
Matched tumor-normal NGS with FACETS analysis detects a range of prognostically relevant alterations in CDKN2A/B and other genes. FACETS showed good concordance with SNP-microarray in a subset of cases (supplemental Fig. 3). Kocakavuk et al. recently described shortened OS across multiple cohorts of IDH-mutant, 1p/19q intact gliomas with CDKN2A HEMIDEL using copy number profiles from NGS/methylation data [3]. These findings emphasize the clinical relevance of detection of CDKN2A/B HEMIDEL in IDHA. [6, 7]. As a molecularly-targeted therapeutic has shown promise in IDH-mutant grade 2 gliomas [5], extending the utility of NGS with bioinformatic tools like FACETS may help to both improve patient management and guide optimal treatment in the future.
Data availability
The datasets analyzed in the current study are available from the corresponding author on reasonable request.
References
Appay R, Dehais C, Maurage C-A, Alentorn A, Carpentier C, Colin C et al (2019) CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas. Neuro Oncol 21:1519–1528. https://doi.org/10.1093/neuonc/noz124
Chakravarty D, Gao J, Phillips SM, Kundra R, Zhang H, Wang J et al (2017) OncoKB: a precision oncology knowledge base. JCO Precis Oncol 2017. https://doi.org/10.1200/po.17.00011
Kocakavuk E, Johnson KC, Sabedot TS, Reinhardt HC, Noushmehr H, Verhaak RGW (2023) Hemizygous CDKN2A deletion confers worse survival outcomes in IDHmut-noncodel gliomas. Neuro Oncol. https://doi.org/10.1093/neuonc/noad095
Mandonnet E, Delattre JY, Tanguy ML, Swanson KR, Carpentier AF, Duffau H et al (2003) Continuous growth of mean tumor diameter in a subset of grade II gliomas. Ann Neurol 53:524–528. https://doi.org/10.1002/ana.10528
Mellinghoff IK, van den Bent MJ, Blumenthal DT, Touat M, Peters KB, Clarke J et al (2023) Vorasidenib in IDH1- or IDH2-mutant low-grade glioma. New Engl J Med. https://doi.org/10.1056/NEJMoa2304194
Perry A, Anderl K, Borell TJ, Kimmel DW, Wang CH, O’Fallon JR et al (1999) Detection of p16, RB, CDK4, and p53 gene deletion and amplification by fluorescence in situ hybridization in 96 gliomas. Am J Clin Pathol 112:801–809. https://doi.org/10.1093/ajcp/112.6.801
Reis GF, Pekmezci M, Hansen HM, Rice T, Marshall RE, Molinaro AM et al (2015) CDKN2A loss is associated with shortened overall survival in lower-grade (World Health Organization Grades II-III) astrocytomas. J Neuropathol Exp Neurol 74:442–452. https://doi.org/10.1097/nen.0000000000000188
Shen R, Seshan VE (2016) FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing. Nucleic Acids Res 44:e131–e131
Shirahata M, Ono T, Stichel D, Schrimpf D, Reuss DE, Sahm F et al (2018) Novel, improved grading system(s) for IDH-mutant astrocytic gliomas. Acta Neuropathol 136:153–166. https://doi.org/10.1007/s00401-018-1849-4
Zehir A, Benayed R, Shah RH, Syed A, Middha S, Kim HR et al (2017) Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med 23:703–713. https://doi.org/10.1038/nm.4333
Funding
This work was funded by P30-CA008748.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Hickman, R.A., Gedvilaite, E., Ptashkin, R. et al. CDKN2A/B mutations and allele-specific alterations stratify survival outcomes in IDH-mutant astrocytomas. Acta Neuropathol 146, 845–847 (2023). https://doi.org/10.1007/s00401-023-02639-0
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00401-023-02639-0